Treatment of idiopathic oligozoospermia with combined human chorionic gonadotropin/human menopausal gonadotrophin: A randomised, double‐blinded, placebo‐controlled clinical study

Abstract

To evaluate whether hCG/hMG therapy has beneficial effects on idiopathic oligozoospermia in Chinese infertility population. The patients were randomly divided into the treatment group receiving hCG/hMG for 3 months and the placebo group receiving placebo for 3 months. Semen and biochemical analysis was performed, and DNA fragmentation as well as spermatid concentration was evaluated. Administration of hCG/hMG for 3 months could significantly improve sperm concentration, rate of forward motile spermatozoa, total motile sperm count, the percentage of sperm with normal morphology and the rate of spontaneous pregnancy in medium‐ and higher‐level inhibin B group respectively. Moreover, in medium‐ and higher‐level inhibin B group, sperm DNA fragmentation index and spermatid concentration were significantly declined respectively at the end of treatment. However, there were no significant differences in lower‐level inhibin B group before and after treatment in term of seminal parameters, DNA fragmentation and spermatid concentration. HCG/hMG therapy for 3 months has a beneficial effect on a part of male with idiopathic oligozoospermia, and the efficacy of hCG/hMG therapy is associated with the inhibin B level.

Sperm DNA fragmentation is a necessity for modern clinical practice

“…По данным метаанализа, выполненного D. Santi и соавт., использование гонадотропинов может положительно влиять на индекс ФДС [28]. Однако по данным двойного слепого плацебокон-тролируемого исследования, проведенного в 2019 г., снижение уровня ФДС у пациентов с идиопатической олигозооспермией происходит только к концу 3-го месяца терапии менопаузным гонадотропином в сочетании с хорионическим гонадотропином человека у пациентов со средним и высоким уровнем ингибина В [64].…”